Is Pelthos Therapeutics Inc. (PTHS) overvalued? · rev $7.4M
Pelthos Therapeutics Inc. (PTHS) is a biotechnology company listed on AMEX.
This page asks whether Pelthos Therapeutics Inc. (PTHS) looks expensive on cached numbers — not a short thesis.
Latest reported PTHS revenue for 2025-09-30 was $7.4M. Net income was -$16.2M. PTHS currently screens at market cap $94.7M.
PTHS currently screens at market cap $94.7M. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next PTHS 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the PTHS stock page for the full model, not this heading.
Not investment advice.